



Fox Chase Cancer Center (FCCC) is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, one of only 41 centers in the country to qualify for this highest level of designation. As a result, Fox Chase physicians and researchers are frequently involved in setting new guidelines for breakthrough medicine and comprehensive care. FCCC is well known for its' groundbreaking research and is home to two Nobel laureates and a Kyoto Prize winner.

A Postdoctoral position is immediately available in the laboratory of Dr. Neil Johnson in the Molecular Therapeutics Program. Our aim is to understand how common cancer-causing mutations in DNA repair genes influence protein function and DNA damage signaling pathways. Ultimately, we will define how mutations in DNA repair genes impact tumor response to anti-cancer therapeutics. Our overarching goal is to develop biomarkers that predict tumor response to standard DNA damaging agent chemotherapies as well as novel DNA repair inhibitors.

Research involves extensive mammalian tissue culture, molecular biology and mouse models of cancer. We are particularly interested in candidates with previous experience in mouse genetics and DNA repair biology. Qualified candidates must be highly dedicated, enthusiastic and prepared to work the necessary hours required to develop a successful and highly productive research career. Strong background in mammalian tissue culture and molecular biology are required. We are considering candidates holding a Ph.D. degree with less than 1-year postdoctoral experience only. Candidates interested in the position should send curriculum vitae, a brief description of research experience, and names of three references to Dr. Neil Johnson (Email: neil.johnson@fcc.edu).

- Wang Y, Kraiss JJ, Bernhardt AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N. [RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance](#). J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25. PubMed PMID: 27454289; PubMed Central PMCID: [PMC4966309](#).
- Wang Y, Bernhardt AJ, Nacson J, Kraiss JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N. [BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance](#). Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6. PubMed PMID: 31827092; PubMed Central PMCID: [PMC6906494](#).
- Nacson J, Di Marcantonio D, Wang Y, Bernhardt AJ, Clausen E, Hua X, Cai KQ, Martinez E, Feng W, Callén E, Wu W, Gupta GP, Testa JR, Nussenzweig A, Sykes SM, Johnson N. BRCA1 Mutational Complementation Induces Synthetic Viability. *Molecular Cell*. 2020 Jun 4;78(5):951-959.e6. doi: 10.1016/j.molcel.2020.04.006. PubMed PMID: 32359443; PMCID: PMC7418109 **(available on 2021-06-04)**